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ABSTRACT
Background: Sevoflurane may prolong the corrected QT
(QTc) interval in healthy humans when administered for
induction and maintenance of anesthesia. Little information
is available about the dose-response relationship of sevoflu-
rane on the QTc interval. We performed a pharmacody-
namic analysis of the relationship between end-tidal sevoflu-
rane concentration (CET) and the QTc.
Methods:Twenty-one patients aged 20–50 yrwere enrolled in
this study. Sevoflurane concentrations were progressively in-
creased and thendecreased over 15min at the start of anesthesia;
CET and automated QT interval were recorded continuously.
Pharmacodynamic analysis using a sigmoid Emax model was
performed to assess the concentration-effect relationship.
Results:Maximal CET was 4.30 0.33%. Measured baseline
and maximally prolonged QTc interval values were 351.7 
15.4ms and 397.8 17.5ms, respectively.During sevoflurane
anesthesia, increased concentrations were correlated with pro-
longed QTc interval. Hysteresis between the CET and QTc
intervalwere observed and accounted for in themodel.Ce50 and
ke0 were 2.5  1.4 and 2.0  1.0, respectively. The median
prediction error, median absolute prediction error, and the co-
efficient of determination (R2) were 0.02%, 0.75%, and 0.95,
respectively. The effect-site concentration (Ce50) and QTc in-
terval data fit to a sigmoid Emax model.
Conclusions: Among patients receiving sevoflurane for an-
esthesia, QTc interval changes correlate to anesthetic level.
The Ce50 for significant QTc change is at clinically relevant
levels of sevoflurane anesthesia.
THEQT interval represents the total duration between theonset of electrical depolarization of the ventricles and the
end of repolarization. Prolongation of the QT interval is an
alteration of the electrocardiogram thatmay result in potentially
dangerous ventricular arrhythmias including tachycardia, fibril-
lation, and asystole, resulting in syncope, seizure-like episodes,
and sudden cardiac death.1–4 Long QT syndrome may result
from exposure to various factors including anesthetic drugs and
cardiac, neurologic, and electrolyte disturbances as well as con-
genital mutation of cardiac ion channels.5,6
Sevoflurane is a popular volatile anesthetic because of its
low blood-gas solubility, which leads to rapid induction and
emergence from anesthesia. In some electrocardiogram stud-
ies, it was shown that sevoflurane prolonged the corrected
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What We Already Know about This Topic
❖ Sevoflurane may prolong the corrected QT (QTc) interval of
the electrocardiogram in healthy patients.
❖ There is little information about the concentration-response
relationship of the effect of sevoflurane on the QTc interval.
What This Article Tells Us That Is New
❖ The QTc interval changes produced by sevoflurane are con-
centration-related.
❖ The QTc interval is prolonged by clinically relevant sevoflurane
concentrations.
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QT (QTc) interval during induction of inhalational anesthe-
sia.7–10 However, there is little published information in the
literature specifying the dose-effect relationship of sevoflu-
rane on the QTc interval.11,12 Pharmacodynamic modeling
can be useful in describing this relationship. The main ob-
jective of this study was to examine the relationship between
end-tidal sevoflurane concentration (CET) and QTc interval




After obtaining approval from the institutional review board
at Yonsei University College of Medicine (Seoul, Korea) and
written informed consent from participants, 21 patients
(American Society of Anesthesiologists Physical Status Clas-
sification P1 or P2) aged 20–50 yr were enrolled in this
study. Patient exclusion criteria were: abnormal serum elec-
trolyte values, a QTc interval duration greater than 440 ms,
concomitant medication known to affect QTc interval dura-
tion (e.g., tricylic antidepressant agents, antidysrhythmics,
-adrenergic antagonists, calcium channel blocking agents),
existence of valvular cardiac disease, any cardiac rhythm
other than sinus rhythm, diabetes mellitus, pregnancy, or
obesity.
All study data were collected in the morning (8:00–10:00
AM) to restrict the effects of day-night changes on the QTc
interval. Patients received no premedication. After patients
were taken into the operating room, electrocardiogrammon-
itoring, pulse oximetry, noninvasive blood pressure, and
fraction of inspired oxygen with CET and carbon dioxide
concentration monitoring were begun. Blood pressure was
measured with an automatic oscillographic device every 2
min during the study period. After the monitoring equip-
ment was attached, patients were allowed to rest for 5 min
while lactated Ringer’s solution, 4 ml/kg, was infused before
inducing anesthesia. A standard real-time automated three-
lead electrocardiogram was continuously recorded using a
data acquisition system (PowerLab; AD Instruments, Colo-
rado Springs, CO). The QT interval was measured in lead II
from the onset of the QRS complex to the end of the T wave,
defined as a return to the TP baseline. When U waves were
present, the nadir between the T andUwaves was regarded as
the end of theQT interval. Biphasic Twaves were considered
finished with the final return to baseline. The values of the
QT interval of four successive beats were averaged. The QT
interval was corrected using the Fridericia formula: QTc 
QT/3(R  R interval).13
Study Measurements
Anesthesia was induced by sevoflurane inhalation only with a
tight-fitting facemask and 6 l/min airflow of 100% oxygen.
The sevoflurane vaporizer was initially set at 1% and was
increased stepwise 1% each minute, up to a maximum va-
porizer setting of 8%. Subsequently, the vaporizer was de-
creased stepwise 1% each minute until sevoflurane was re-
turned to 1%. As spontaneous breathing diminished,
patients were manually assisted via facemask while an ex-
haled tidal volume of 8 ml/kg was maintained. Respiratory
rate was adjusted to maintain an end-tidal carbon dioxide
partial pressure of 35 mmHg. No other drugs were adminis-
tered and the patients were left unstimulated during the
study period. After the measurements were completed, anes-
thesia was continued according to the individual needs of the
patient and type of surgical intervention: opioids, muscle
relaxants, tracheal intubation, or laryngeal mask airway, as
required.
Data Analysis and Model Selection
CET and corresponding QTc interval data along with demo-
graphic information were used to develop a pharmacody-
namic model using NONMEM (nonlinear mixed effects
modeling) software (version VII; GloboMax, Hanover,
MD). The model provides estimates of the population mean
parameters, interindividual, and residual random effects.
The pharmacodynamic model was run using the first-order
conditional estimation method with interindividual-residual
interaction to determine parameter estimates. To account for
the delay between CET measurements and the drug concen-
tration at the site of drug effect, an effect compartment (Ce)
was modeled. It was assumed that CET was linearly linked to
Ce, which was estimated with the use of the following equa-
tion. dCe/dt (CET Ce) ke0, where ke0 is the first-order
rate constant determining the equilibration between the two.
The Ce over time was calculated as the convolution of the
end-tidal concentrations over time with the disposition func-
tion of the effect site. The convolution was based on a “con-
nect-the-dots” approach, previously used by Schnider et al.14
The ke0 was estimated by minimizing the area of the hyster-
esis loop of QTc data versus CET. One individual ke0 value
was calculated for each patient on the basis of his or her
particular inhalation anesthetic ramp. The relationship be-





E0 is the baseline QTc interval in the absence of sevoflurane,
Emax is themaximum increase in theQTc interval,Ce50 is the
effect-site sevoflurane concentration required to achieve
50% of the maximum increase in the QTc interval, and  is
the steepness of the concentration-response relation curve.
Interindividual variability in E0, Emax, Ce50, , and ke0
was modeled using an exponential error model. Residual
intraindividual variability was modeled using additive error
model. In our modeling approach, we first developed the
base population model without covariates included. Then,
we explored additional covariates of sex, age, height, and
weight successively to determine their impact on estimates of
the model parameters.
Statistical Analysis
For model assessment, the minimum value of the objective
function was considered together with the model parameter
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estimates, median prediction error, median absolute predic-
tion error, and the coefficient of determination (R2). For
each analysis, NONMEM computed the minimum value of
the objective function, a statistic that is proportional to mi-
nus twice the log likelihood of the data. Covariates were
added using a forward addition/backward substitution ap-
proach. A covariate was considered significant when its in-
clusion lowered theminimum value of the objective function
by at least 3.85 points. The difference in minimum value of
the objective function between two nestedmodels in approx-
imately chi-square distribution and can be used for signifi-
cance tests (P  0.05, with 1 degree of freedom). Data are
presented as mean SD.
Results
Twenty-one patients completed the study (table 1). Ade-
quate airway management was obtained in all patients with-
out requiring insertion of an oral airway. Peripheral oxygen
saturation was maintained above 95% throughout the study
Fig. 1. The time course of the measured QTc interval change (A) and of the sevoflurane end-tidal and estimated effect-site
concentrations (B) in all patients. QTc interval  corrected QT interval.
Table 1. Patient Characteristics (N  21)
Characteristic Mean  SD Range
Sex
Men, no. 9 —
Women, no. 12 —
Age, yr 37.1  8.6 21–49
Weight, kg 61.0  8.1 52–78
Height, cm 163.7  7.7 150–178
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period in all patients. Maximal CET was 4.30  0.33%.
Among the total 5,347 measurements of QTc interval, the
measurements that were made for the 15 s before changing
the CET were used for modeling the concentration-QTc re-
lationship. It was anticipated that these 1,220 measurements
were more closely equilibrated to the Ce50.
Mean baseline QTc interval values were 351.7  15.4
ms, with values ranging from 320.8–377.2 ms and showing
a relatively wide dispersion. The mean maximally prolonged
QTc interval value observed during the study period was
397.8  17.5 ms. All patients maintained a normal sinus
rhythm during the study despite the prolongedQTc interval.
Figure 1 shows the time course of the CET and changes in
QTc interval in all patients where increased concentrations
were correlated with prolongation of QTc interval. Two pa-
tients showed the maximal prolongation of QTc interval at
approximately 1% sevoflurane concentration after which
their QTc interval decreased slightly despite increasing
sevoflurane concentration. Data from those two patients
were excluded from concentration effect modeling to im-
prove the stability of the pharmacodynamic model. For the
remaining 19 patients, plotting CET versus QTc interval in
time order revealed counterclockwise hysteresis (fig. 2A),
which collapsed by introduction of Ce50 (fig. 2B). The rela-
tionship between the observed and the post hoc Bayesian pre-
dicted QTc interval versus Ce50 is plotted in figure 3. For
these 19 subjects, the QTc interval increased with increasing
Ce and a sigmoid Emax model could be fitted to the data. The
predicted QTc interval calculated using the parameters de-
rived from the sigmoid Emax model was plotted against the
measured QTc interval for comparison (fig. 4).
The mean  SD estimates of all parameters for the sig-
moid Emax model are summarized in table 2. The Ce50 and
ke0 were 2.5 1.4% and 2.0 1.0 min
1, respectively. The
residual variability (residual error ) for sigmoid Emax model
was 4.5. The median prediction error, median absolute pre-
diction error, and R2 were 0.02%, 0.75%, and 0.95, respec-
tively. Demographic variables did not influence the param-
eters in the model for the analyzed subjects.
Sevoflurane administration did not significantly alter the
heart rate. Sevoflurane produced a concentration-dependent
reduction of mean arterial pressure. The lowest mean arterial
pressure values recorded in each patient were 67.8  9.4
mmHg.
Discussion
This was the first study to apply a pharmacodynamic model
to quantitatively describe the effect of sevoflurane on QTc
Fig. 2. The relationship between QTc interval and the end-tidal sevoflurane concentration (A) and effect-site sevoflurane
concentration (B) for two representative patients. The gray dotted arrows indicate the counter-clockwise hysteresis. QTc
interval  corrected QT interval.
Fig. 3. (A) Observed raw QTc interval versus the calculated sevoflurane effect-site concentration. (B) The thin gray lines
represent individual predicted values of QTc interval, whereas the bold black line represents the typical curve of the population
data. QTc interval  corrected QT interval.
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interval. Increasing sevoflurane concentration had a pro-
nounced effect on QTc interval in 19 of 21 subjects, pro-
longing it by up to an average maximal value of 46 ms. This
result corresponds to a maximum increase of around 13%
compared with the baseline QTc interval. The extent of
sevoflurane-associated QTc prolongation might be of clini-
cal significance for patients presenting with the long QT
syndrome, hypokalemia, or in presence of other drugs or
factors that lengthen QTc.2,15 Among patients presenting
with a prolongedQTc interval, the choice of sevofluranemay
be considered with caution.
There are few publications in the literature in which
sevoflurane dose or end-tidal concentration versusQT inter-
val response was investigated, making it unclear whether
sevoflurane prolongsQTc interval in a dose-dependentman-
ner.11,12 It is probably difficult to determine the effects of
individual anesthetic agents because most of the drugs in
clinical anesthetic practice may interfere with the duration of
the QTc interval. Whyte et al.12 suggested that sevoflurane
non–dose dependently prolonged the QTc interval in
healthy children, whereas sevoflurane (1–4%) prolonged
QTc in a dose-dependent manner in guinea pigs as re-
ported by Yamada et al.11 It is not easy to explain the
discrepancies between these studies, but it is likely that the
result of the former study might be attributed to an insuf-
ficient number of subjects and the use of a relatively short
range of sevoflurane concentrations (0.010–0.015 mini-
mum alveolar concentration).12
The experimental design in this study was chosen to allow
enough time at a particular CET for the effect-site to ap-
proach equilibration. Given that the average effect-site time
constant was 2.0min1, which would equate to an effect-site
half-life of 0.35 min, the experiment design represents a rea-
sonable compromise that allows for the accurate assessment
of the effect but still provides an anesthetic induction that is
typical of daily clinical practice. The effect-site compart-
ment, estimated from the hysteresis observed by plottingCET
versusQTc interval, allowed us to estimate Ce50 and account
for the delay in onset and offset of effect. This method allows
the QTc effect to be studied during non–steady state condi-
tions and provides an estimate of the equilibration rate be-
tween CET, a variable that is clinically available, and the
blood-myocardium equilibration time.16 The mean value of
QTc ke0 in our data (2.0 min
1) was faster than the ke0 of
processed electroencephalogram, representing the main an-
esthetic effect of sevoflurane on the central nervous sys-
tem.17–20 Our results suggest that the QTc interval reacted
faster to changes in sevoflurane concentration than the pro-
cessed electroencephalogram would. This difference is prob-
ably explained by more rapid equilibration between blood
and myocardium than between blood and brain.
The values of E0 and Emax had high interindividual vari-
ability. This variability could be due to the different baseline
values of QTc interval by sex.21 Both raw QTc values of
baseline (355.1 14.3 ms) and maximal (403.3 13.4 ms)
prolongation in women were greater than those observed in
men (346.0  16.5 ms and 388.9  20.4 ms, respectively)
(data not shown). Unfortunately, sex as a covariate did not
significantly improve the model fit to the data. The reason
for this lack of effect is unclear, but it could be due to a study
design that uses a relatively small patient cohort. According
to the pharmacodynamic modeling, half of the maximal
change in QTc interval, 29.0 ms, could result from a Ce50
value of 2.5%. Our findings are comparable with those of
other studies, which showed 22–26-ms changes in QTc
interval with steady state levels of 2.0 –2.5% sevoflurane
anesthesia.7,8,10
The predicted mean values of Emax and Ce50 should be
considered with caution. Some patient data showed that the
predicted QTc interval versus effect-site sevoflurane concen-
tration curve did not plateau to the maximum effect at con-
centrations within the range of the current data. Therefore,
this estimate of the Emax was an indirect measure dependent
on the curvature present in the available data rather than a
direct measure of an actual plateau in all the data. The pre-
dicted mean value of Ce50 was consequently larger than an-
ticipated from review of the raw data.
The two patients whose data were excluded when build-
ing our model showed sudden increased heart rates at the
early phase of increasing sevoflurane concentration, which
Fig. 4. The relationship between the observed and individual
predicted values of QTc interval. The solid line represents the
line of identity. QTc interval  corrected QT interval.
Table 2. Pharmacodynamic Model Parameters: Effect
of Sevoflurane on Corrected QT Prolongation
Parameter Mean  SD
E0, ms 354.6  15.2
Emax, ms 412.5  27.2
Ce50, % 2.5  1.4
 2.0  0.8
ke0, min
1 2.0  1.0
Ce50  effect-site sevoflurane concentration required to achieve
50% of maximum increase in the corrected QT interval; E0 
baseline corrected QT interval in absence of sevoflurane; Emax 
maximum increase in corrected QT interval; ke0  first-order rate
constant determining the efflux from the effect-site;   slope of
sigmoid relation between sevoflurane end-tidal concentration
and effect.
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altered the ability to determine changes in QTc. The absence
of premedication may have produced anxiety, which might
manifest as tachycardia.22 Several stimuli leading to sympa-
thetic stimulation, such as anxiety, emotional stress, physical
stress, and loud auditory stimulation, may prolong QTc in-
tervals.15,23 Hence the use of premedication for preventing
the release of catecholamine may be helpful for patients with
QTc prolongation. To avoid the confounding effects of
other agents in our analysis, the patients in this study received
no premedication.
The Bazett correction is the method most commonly em-
ployed to correct the QT interval for changes in heart rate in
clinical electrocardiogram practice. However, this method is
known to overcorrect the QT interval for fast heart rate and
undercorrect it for slow heart rate—potentially leading to
false diagnosis of QTc interval, especially given that heart
rate can be extremely dynamic during general anesthesia.24
The fixed exponent Fridericia correction is considered a
much better approach,25 although there is no standard
method of heart rate correction in the QTc interval.25–27
We conclude that QTc interval changes correlate to
sevoflurane concentration and are significant at clinically rel-
evant concentrations. The concentration-response curves
could be adequately described with a sigmoid Emax model,
using effect compartment concentrations rather than CET as
independent variable. Despite the absence of cardiac arrhyth-
mias, patients with congenital or acquired prolonged QTc
interval might need to be monitored closely at clinically rel-
evant levels of sevoflurane anesthesia.
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